Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...